Recall of Philips respiratory devices classified as most serious by USFDA
The ventilators being recalled include Trilogy Evo, Evo O2 and EV300, among others.
Netherlands: The U.S. Food and Drug Administration (FDA) on Monday classified the recall of Philips' respiratory machines as its most serious type, as their use could cause serious injuries or death.
The Dutch medical devices maker started the process on March 29 and has recalled 73,000 devices in the United States.
The ventilators being recalled include Trilogy Evo, Evo O2 and EV300, among others. These devices help people with respiratory conditions to keep breathing at a regular rhythm.
Philips was recalling the ventilators after detecting contaminants such as dust and dirt from the environment in the air path of some devices.
Read also: Philips makes USD 631 million provision for recall litigation costs
The company has received 542 reports about this issue, according to the FDA. The health agency said there are currently two reported injuries and one death attributable to the issue.
The devices were distributed between March 26, 2019 and March 22, 2023.
Read also: Philips respiratory devices recall classified as most serious by USFDA
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.